CBLL1 and neoplasm: In conclusion, our results underline that CMS2 patients with high CBLL1 expression and poor survival showed the worst prognosis (like CMS4 tumours), further highlighting CBLL1 expression as a clear marker of CMS2 patients with worse prognosis.